Enhanced T-cell therapy targeting NY-ESO-1: Phase I/II started

Adaptimmune began an open-label, U.S. Phase I/II trial to evaluate a single dose of enhanced T-cell therapy targeting NY-ESO-1 in up to 10 patients with the HLA-A*0201, HLA-A*0205 and/or HLA-A*0206 al...